Patterns of clinically detectable treatment effects with galantamine: A qualitative analysis

Dementia and Geriatric Cognitive Disorders

Volumn 15, Issue 1, 2003, Pages 26-33

  Joffres, Christine ^a   Bucks, Romola S ^a   Haworth, Judy ^a   Wilcock, Gordon K ^a   Rockwood, Kenneth ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Alzheimer's disease; CIBIC Plus; Clinical meaningfulness; Clinical trials; Galantamine

Indexed keywords

GALANTAMINE; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHYSICIAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CAREGIVERS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS, PHASE III; DOUBLE-BLIND METHOD; FEMALE; GALANTAMINE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MIDDLE AGED; MULTICENTER STUDIES; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0037211648     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066673     Document Type: Article

References (21)

1. Leber PD: Developing safe and effective antidementia drugs; in Becker R, Giacobini E (eds): Alzheimer Disease: From Molecular Biology to Therapy. Boston, Birkhäuser, 1997, pp 579-584.
2. Schneider LS, Olin JT: Clinical global impression in Alzheimer's clinical trials. Int Psychogeriatr 1996;8:277-288, discussion 288-290.
3. Rockwood K, Stolee P: Responsiveness of outcome measures used in an antidementia drug trial. Alzheimer Dis Assoc Disord 2000;4:182-185.
4. Olin JT, Schneider LS, Doody RS, Clark CM, Ferris SH, Morris JC, Reisberg B, Schmitt FA: Clinical evaluation of global change in Alzheimer's disease: Identifying consensus. J Geriatr Psychiatry Neurol 1996;9:176-180.
5. Rockwood K: Use of global assessment measures in dementia drug trials. J Clin Epidemiol 1994;47:101-103.
6. Rockwood K, MacKnight C: Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology 2001;20:51-56.
7. Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, Rockwood K, Schneider L, Takeda M, Tariot P, Wilkinson D: Pharmacotherapy of Alzheimer's disease: Is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001;16:653-666.
8. Feinstein AR: 'Clinical judgment' revisited: The distraction of quantitative models. Ann Intern Med 1994;120:802.
9. Feinstein AR: Clinimetrics. New Haven, Yale University Press, 1987.
10. Goering PN, Streiner DL: Reconcilable differences: The marriage of qualitative and quantitative methods. Can J Psychiatry 1996;41:491-497.
11. Joffres C, Graham JE, Rockwood K: A qualitative analysis of the Clinician Interview-Based Impression of Change (Plus): Methodological issues and implications for clinical research. Int Psychogeriatr 2000;12:403-413.
12. Wilcock GK, Lilienfeld S, Gaens E: Safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000;321:1445-1449.
13. Patton MQ: Qualitative Evaluation and Research Methods. Newbury Parks, Sage, 1990.
14. Strauss A, Corbin J: Grounded theory methodology: An overview; in Denzin NK, Lincoln YS (eds): Handbook of Qualitative Research. Thousand Oaks, Sage, 1994, pp 273-285.
15. Strauss A, Corbin J: Basics of Qualitative Research: Grounded Theory Procedures and Techniques. Newbury Park, Sage, 1998.
16. Miles MB, Huberman AM: Qualitative Data Analysis: An Expanded Sourcebook, Ed 2. Newbury Park, Sage, 1994.
17. Rockwood K, Stolee P, Howard K, Mallery L: Use of goal attainment scaling to measure treatment effects in an antidementia drug trial. Neuroepidemiology 1996;15:246-256.
18. Rockwood K, Graham JE, Fay S: Does treatment with donepezil meet the goal of patients with Alzheimer's disease, their caregivers and physicians? Neurology 2001;56(suppl 3):A338.
19. Raskind MA, Peskind ER, Wessel T, Yuan W: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-2268.
20. Rockwood K, Mintzer J, Truyer H, Wessel T, Wilkinson D: Effects of a flexible galantamine dose in Alzheimer's disease: A randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-595.
21. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C: A 5 month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2262-2276.